Table 2.
PCL5 symptom severity at hospitalization and follow-up based on genotype.
| Gene SNP | Group | Allele (N) | Mean (SD) PTSD symptom severity hospitalization | Mean (SD) PTSD symptom severity follow-up |
|---|---|---|---|---|
| FAAH rs324420 | All | A/A | 21.85 (19.87) | 34.47 (22.35) |
| (20) | ||||
| C/A | 19.39 (15.31) | 21.3 (19.67) | ||
| (67) | ||||
| C/C | 18.12 (17.47) | 16.83 (19.01) | ||
| (81) | ||||
| PCL5 at Hospitalization: [F(2,165) = 0.407, p = 0.666]; PCL5 follow-up: [F(2,165) = 6.496, p = 0.002] | ||||
| Men | A/A | 16.63 (13.47) | 33.00 (21.11) | |
| (16) | ||||
| C/A | 19.4 (15.71) | 20.76 (19.68) | ||
| (50) | ||||
| C/C | 13.88 (12.82) | 11.34 (17.03) | ||
| (50) | ||||
| PCL5 at hospitalization: [F(2,113) = 1.882, p = 0.157]; PCL5 follow-up: [F(2,113) = 8.760, p < 0.001] | ||||
| Women | A/A | 42.75 (29.41) | 40.37 (29.65) | |
| (4) | ||||
| C/A | 19.35 (14.54) | 22.88 (20.13) | ||
| (17) | ||||
| C/C | 24.97 (21.62) | 25.68 (18.94) | ||
| (31) | ||||
| PCL5 at hospitalization: [F(2,49) = 2.192, p = 0.12]); PCL5 at follow-up: [F(2,49) = 1.224, p = 0.303] | ||||
| Minorities | A/A | 23.24 (20.83) | 39.56 (20.17) | |
| (17) | ||||
| C/A | 23.34 (16.37) | 29.24 (20.12) | ||
| (38) | ||||
| C/C | 22.88 (17.94) | 26.71 (21.7) | ||
| (34) | ||||
| PCL5 at hospitalization: [F(2,86) = 0.006, p = 0.994]; PCL5 at follow-up: [F(2,86) = 2.251, p = 0.111] | ||||
| African Americans | A/A | 23.24 (20.83) | 39.56 (20.17) | |
| 17 | ||||
| C/A | 24.53 (17.39) | 28.47 (19.42) | ||
| 32 | ||||
| C/C | 24.04 (19.29) | 30.27 (21.86) | ||
| 26 | ||||
| PCL5 at Hospitalization: [F(2,72) = 0.026, p = 0.974]; PCL5 follow-up: [F(2,72) = 1.715, p = 0.187 | ||||
| CNR1 rs806371 | All | G/G | 20.13 (10.75) | 31.00 (24.58) |
| (8) | ||||
| G/T | 21.36 (17.39) | 24.58 (21.45) | ||
| (45) | ||||
| T/T | 18.1 (17.06) | 18.48 (19.28) | ||
| (115) | ||||
| PCL5 at hospitalization: [F(2,165) = 0.613, p = 0.543]; PCL5 at follow-up: [F(2,165) = 2.580, p = 0.079] | ||||
| Men | G/G | 21.17 (11.14) | 24.17 (24.77) | |
| (6) | ||||
| G/T | 21.13 (16.68) | 23.06 (22.28) | ||
| (32) | ||||
| T/T | 14.45 (13.11) | 16.03 (18.47) | ||
| (78) | ||||
| PCL5 at hospitalization: [F(2,113) = 2.868, p = 0.061]; PCL5 at follow-up: [F(2,113) = 1.687, p = 0.190 | ||||
| Women | G/G | 17.00 (12.73) | 51.50 (6.36) | |
| (2) | ||||
| G/T | 21.92 (19.74) | 28.31 (19.58) | ||
| (13) | ||||
| T/T | 25.81 (21.53) | 23.66 (20.18) | ||
| (37) | ||||
| PCL5 at hospitalization: [F(2,49) = 0.299, p = 0.743]; PCL5 at follow-up: [F(2,49) = 1.994, p = 0.147] | ||||
| Minorities | G/G | 20.13 (10.75) | 31.00 (24.58) | |
| (8) | ||||
| G/T | 25.38 (16.62) | 32.55 (20.94) | ||
| (29) | ||||
| T/T | 22.37 (19.14) | 28.84 (20.87) | ||
| (52) | ||||
| PCL5 at hospitalization: [F(2,86) = 0.394, p = 0.676]; PCL5 at follow-up: [F(2,86) = 0.291, p = 0.748] | ||||
| CNR1 rs1049353 | All | A/A | 16.67 (15.91) | 16.83 (21.61) |
| (6) | ||||
| G/A | 18.16 (17.89) | 20.98 (20.54) | ||
| (43) | ||||
| G/G | 19.52 (16.68) | 20.81 (20.34) | ||
| (199) | ||||
| PCL5 at hospitalization: [F(2,165) = 0.164, p = 0.849]; PCL5 at follow-up: [F(2,165) = 0.113 p = 0.893] | ||||
| Men | A/A | 12.75 (11.5) | 12.00 (14.72) | |
| (4) | ||||
| G/A | 14.75 (16.11) | 19.18 (21.47) | ||
| (28) | ||||
| G/G | 17.45 (13.89) | 18.43 (19.87) | ||
| (84) | ||||
| PCL5 at hospitalization: [F(2,113) = 0.521, p = 0.595]; PCL5 at follow-up: [F(2,113) = 0.223, p = 0.801] | ||||
| Women | A/A | 24.50 (26.16) | 26.50 (37.48) | |
| (2) | ||||
| G/A | 24.53 (19.83) | 24.33 (18.92) | ||
| (15) | ||||
| G/G | 24.49 (21.42) | 26.53 (20.59) | ||
| (35) | ||||
| PCL5 at hospitalization: [F(2,49) = 0.000, p = 1.000]; PCL5 at follow-up: [F(2,49) = 0.060, p = 0.941] | ||||
| Minorities | A/A | 43.00 () | 53.00 () | |
| (1) | ||||
| G/A | 26.64 (21.63) | 41.91 (19.58) | ||
| (11) | ||||
| G/G | 22.39 (17.1) | 28.28 (20.78) | ||
| (77) | ||||
| PCL5 at hospitalization: [F(2,86) = 0.915, p = 0.405]; PCL5 at follow-up: [F(2,86) = 2.711, p = 0.072] | ||||
| CNR1 rs2180619 | All | A/A | 15.22 (14.7) | 13.73 (15.64) |
| (37) | ||||
| G/A | 19.28 (17.55) | 22.3 (21.17) | ||
| (86) | ||||
| G/G | 21.39 (17.13) | 23.15 (21.02) | ||
| (46) | ||||
| PCL5 at hospitalization: [F(2,166) = 1.407, p = 0.248]; PCL5 at follow-up: [F(2,166) = 2.851, p = 0.061] | ||||
| Men | A/A | 14.35 (13.99) | 12.35 (15.49) | |
| (26) | ||||
| G/A | 17.53 (14.76) | 21.27 (21.51) | ||
| (60) | ||||
| G/G | 16.32 (14.07) | 17.65 (19.45) | ||
| (31) | ||||
| PCL5 at hospitalization: (F(2,114) = 0.447, p = 0.641); PCL5 at follow-up: [F(2,114) = 1.868, p = 0.159] | ||||
| Women | A/A | 17.27 (16.79) | 17.00 (16.23) | |
| (11) | ||||
| G/A | 23.31 (22.56) | 24.67 (20.57) | ||
| (26) | ||||
| G/G | 31.87 (18.55) | 34.53 (20.08) | ||
| (15) | ||||
| PCL5 at hospitalization: [F(2,49) = 1.715, p = 0.191]; PCL5 at follow-up: [F(2,49) = 2.636, p = 0.082] | ||||
| Minorities | A/A | 21.00 (24.99) | 34.60 (16.41) | |
| (5) | ||||
| G/A | 21.66 (17.79) | 29.35 (21.9) | ||
| (53) | ||||
| G/G | 25.25 (16.79) | 30.44 (20.62) | ||
| (32) | ||||
| PCL5 at hospitalization: [F(2,87) = 0.434, p = 0.649]; PCL5 at folow-up: [F(2,87) = 0.149, p = 0.862] | ||||
PCL5 is the total symptom severity score for the PTSD checklist for the DSM-5.